Safeguarding Lean Mass: How to Prevent Muscle Waste on GLP-1 Medications

The introduction of GLP-1 receptor agonists—such as semaglutide and tirzepatide—has completely shifted the paradigm of weight management. However, a distinct clinical hurdle has taken center stage: the vulnerability of lean tissue. While these treatments excel at reducing overall body weight, data indicates that roughly 25% to 45% of that drop can come directly from lean body mass, which includes your skeletal muscle. This is a noticeable jump from the 25% typical of standard lifestyle interventions. Interestingly, real-world data tracking patient outcomes over 12 months reveals that tirzepatide can lead to about a 2% greater reduction in lean mass compared to semaglutide, largely driven by its higher overall weight-loss velocity. 3 Strategies to Mitigate Muscle LossListen to the podcast episode or read the blog article!